News

Earlier this week, Teladoc Health reported quarterly results showing a 4% year-on-year revenue decline, missing analyst expectations on both revenue and EBITDA and issuing guidance for the next quarter that also fell short of forecasts. The results highlighted a 9.2% average drop in customer spending over recent years despite user growth, alongside expectations for another period of lower revenue and negative earnings per share, underscoring pressure on Teladoc’s core business model. Now...

Teladoc (TDOC) concluded the recent trading session at $6.28, signifying a -2.33% move from its prior day's close.

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Teladoc (NYSE:TDOC) and the best and worst performers in the online marketplace industry.

Teladoc (TDOC) reached $6.16 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

Teladoc Health's growth is supported by chronic care, international expansion and Teladoc One, but BetterHelp weakness and losses temper the outlook.

Over the past six months, Teladoc has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $6.36, representing a healthy 23.2% increase. This run-up might have investors contemplating their next move.

Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Teladoc Health (TDOC) is back in focus after long serving director David B. Snow Jr. notified the company on August 10, 2026 of his plan to retire from the board on September 30. See our latest analysis for Teladoc Health. At a share price of US$6.20, Teladoc Health has seen its 30 day share price return fall 29.3%, while the 1 year total shareholder return is down 19.2%. This points to fading momentum as investors weigh execution risks around BetterHelp and wider virtual care demand. If this...

TDOC's BetterHelp faces a capacity crunch as insurance demand surges, putting therapist recruitment and credentialing at the center.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

Whether it be online shopping or social media, secular forces are propelling consumer internet businesses forward. But it’s not all sunshine and rainbows as consumer purchasing power can make or break demand. This unpredictability is weighing on the industry as its 7.6% return over the past six months has fallen short of the S&P 500’s 11.7% gain.

Insurance demand accelerates faster than expected, straining provider capacity.

Digital medical services platform Teladoc Health (NYSE:TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 15.5% above analysts’ consensus estimates.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Teladoc Health (TDOC) shares came under focus after the company reported second quarter 2026 results, which showed lower sales and a wider net loss, alongside fresh revenue and earnings guidance for the rest of the year. See our latest analysis for Teladoc Health. The earnings release and updated guidance appear to be weighing heavily on sentiment. Teladoc Health's share price return is down 28.32% over the past day and 24.02% over the past week, while the 1-year total shareholder return has...

Teladoc stock sinks on disappointing Q2 revenue and future guidance. Here’s why caution is warranted in buying the dip in TDOC shares today.

Moby summary of Teladoc Health, Inc.'s Q2 2026 earnings call

Teladoc Health (NYSE:TDOC) reported second-quarter results within its consolidated guidance range, supported by stronger-than-expected profitability in its Integrated Care segment, while lower cash-pay revenue at BetterHelp prompted the company to reduce its full-year revenue outlook. Consolidated

Demand for the mental health unit’s insurance offering accelerated faster than expected, eating into its cash pay business. The quarter marked an “unfortunate setback” for BetterHelp, one analyst said.

In late July 2026, Teladoc Health, Inc. reported second-quarter 2026 results showing sales of US$606.93 million and a net loss of US$38.91 million, with both revenue and per-share loss slightly weaker than the same period a year earlier. Over the first half of 2026, Teladoc’s sales declined to US$1.22 billion while its net loss narrowed to US$102.75 million, indicating that cost controls and efficiency measures may be helping even as top-line growth remains under pressure. We will now...

The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Teladoc (TDOC) delivered earnings and revenue surprises of +12.50% and -1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Digital medical services platform Teladoc Health (NYSE:TDOC) will be announcing earnings results this Wednesday after the bell. Here’s what investors should know.

HCA (HCA) delivered earnings and revenue surprises of +0.26% and 0.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A new ChatGPT feature allows users to securely connect personal health data, enabling more personalized, context-aware responses to everyday health questions.